Table 1 Characteristics of the studies included in the systematic review
From: Terlipressin for the treatment of septic shock in adults: a systematic review and meta-analysis
Study | Arms | n | Age(years) | Design | Dosage | Progonstic index | Time(hours) | MAP objective(mmHg) |
|---|---|---|---|---|---|---|---|---|
Morelli et al 2009 [12] | NE | 15 | 64 (59-72) | RCT | 15μg/min | 58 (52-68) (SAPS II) | 48 |  |
NE+TP | 15 | 67 (60-71) | 1.3μg/Kg.h | 62 (57-72) (SAPS II) | 48 | 70±5 | ||
NE+AVP | 15 | 66 (60-74) | 0.03μ/min | 60 (49-66) (SAPS II) | 48 |  | ||
Albanese et al 2005 [18] | NE | 10 | 65 (24-76) | RCT | 0.3μg/kg.min | 29 (24-31) (APACHE II) | 6 | 65-75 |
TP | 10 | 66 (23-79) | OL | 1mg bolus | 28 (24-30) (APACHE II) | 6 | ||
Xiao et al 2016 [19] | NE | 17 | 62±14 | RCT | >0.5μg/kg.min |  | 6 | ≥65 |
NE+TP | 15 | 63±11 | SB | 1.3μg/Kg.h | ||||
Chen et al 2017 [20] | NE | 26 | 55.7±16.1 | RCT | >1μg/kg.min | 20.8±5.7 (APACHE II) | 72 | 65-75 |
TP | 31 | 58.5±17.8 | SB | 0.01-0.04u/min | 23.1±5.2 (APACHE II) | 72 | ||
Choudhury et al 2017 [21] | NE | 42 | 46.76±12.11 | RCT | 7.5-60μg/min |  | 48 | >65 |
TP | 42 | 48.29±12.53 | OL | 1.3-5.2μg/min | 48 | |||
Liu et al 2018 [22] | NE | 266 | 61.09±16.20 | RCT | 4-30μg/min | 19.09 ± 8.26 (APACHE II) | 168 | 65-75 |
TP | 260 | 60.93±15.86 | DB | 20-160μg/h | 19.08 ± 7.01 (APACHE II) | 168 | ||
Hua et al 2013 [24] | DA | 16 | 52.2±14 | RCT | 20μg/Kg.min | 17.6 ± 5.3 (APACHE II) | 48 | 70±5 |
TP | 16 | 56.6±16.4 | 1.3μg/Kg.h | 19.3 ± 9.6 (APACHE II) | 48 | |||
Morelli et al 2008 [23] | NE | 20 | 67 (29-83) | RCT | 0.9μg/Kg.min | 59±10 (SAPS II) | 4 | 70±5 |
NE+TP | 19 | 66 (28-84) | 1mg bolus | 60±12 (SAPS II) | 4 | |||
NE+TP+DA | 20 | 66 (37-82) | 3-20μg/Kg.min | 61±12 (SAPS II) | 4 | |||
Svoboda et al 2012 [25] | NE | 17 | 75 (48-88) | RCT | >0.6μg/Kg.min |  | 72 | 70±5 |
NE+TP | 13 | 70 (37-87) | DB | 4mg/24h | 72 |